NCT02626338View on ClinicalTrials.gov

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Interventions
DRUG

Crenolanib

DRUG

Mitoxantrone

DRUG

Cytarabine

DRUG

Etoposide

DRUG

Fludarabine

DRUG

G-CSF

DRUG

Idarubicin

Trial Locations (4)

72205

University of Arkansas, Little Rock

75390

University of Texas Southwestern Medical Center, Dallas

77030

Houston Methodist, Houston

91010

City of Hope Medical Center, Duarte

Sponsors
All Listed Sponsors
lead

Arog Pharmaceuticals, Inc.

INDUSTRY

NCT02626338 - Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML | Biotech Hunter | Biotech Hunter